Invention Grant
- Patent Title: Tuberculosis vaccines comprising antigens expressed during the latent infection phase
- Patent Title (中): 包含在潜伏感染期间表达的抗原的结核病疫苗
-
Application No.: US13623733Application Date: 2012-09-20
-
Publication No.: US08703151B2Publication Date: 2014-04-22
- Inventor: Claus Aagaard , Carina Vingsbo-Lundberg , Peter Anderson
- Applicant: Statens Serum Institut
- Applicant Address: DK Copenhagen S
- Assignee: Statens Serum Institut
- Current Assignee: Statens Serum Institut
- Current Assignee Address: DK Copenhagen S
- Agency: Knobbe Martens Olson & Bear LLP
- Priority: DKPA200500924 20050623; DKPA200501393 20051005
- Main IPC: A61K39/04
- IPC: A61K39/04 ; A61K39/02 ; C07H21/04

Abstract:
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
Public/Granted literature
- US20130095132A1 TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE Public/Granted day:2013-04-18
Information query